Hemispherx Biopharma Announces Financial Results in its Quarterly Report for the Nine Months Ended September 30, 2016

by Barry101 | Nov 14, 2016 | Press Release

Conference Call Scheduled for Tuesday, November 15, 2016 at 11:00 AM ESTPHILADELPHIA, Nov. 14, 2016 — Hemispherx Biopharma (NYSE:HEB) announces the filing of its Quarterly Report and its financial results for the nine months ended September 30, 2016. The net...

Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on November 15, 2016

by Barry101 | Nov 10, 2016 | Press Release

PHILADELPHIA, Nov. 10, 2016 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates filing its 2016 third quarter financial results for the quarter ended September 30, 2016 on...

Hemispherx Biopharma Featured in Corporate America News Magazine Special Report “Capturing the Power of Immune Response to Treat Disease: Biotech Bounce Back”

by Barry101 | Nov 8, 2016 | Press Release

PHILADELPHIA, Nov. 08, 2016 — Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) has posted an article from Corporate America News magazine, released on October 31, 2016, which features the Company and its...

Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen® Phase III Trial in Patients with CFS/ME

by Barry101 | Oct 31, 2016 | Press Release

51% of patients in the high responder subset receiving Ampligen vs. 18% of placebo patients demonstrated improvement of at least 25% in exercise tolerance Dr. Daniel Peterson; Dr. David Strayer, Hemispherx Biopharma Chief Scientific & Medical Officer; and...

Hemispherx Biopharma Announces Completion of Ampligen® Manufacturing Technology Transfer Milestone

by Barry101 | Oct 19, 2016 | Press Release

PHILADELPHIA, Oct. 19, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) (“Hemispherx” or the “Company”) announced today that it has completed its technology transfer of the Ampligen® manufacturing processes to Avrio Biopharmaceuticals...

Hemispherx Biopharma Announces Granting of Final Settlement of Derivative and Class Action Case

by Barry101 | Sep 22, 2016 | Press Release

PHILADELPHIA, Sept. 22, 2016 — Hemispherx Biopharma (NYSE MKT:HEB) (the “Company”), announced today that the Court of Chancery of the State of Delaware has issued an order granting final approval of a settlement of the derivative and class action...